2511 — HighTide Therapeutics Share Price
0.000.00%
Last trade - 00:00- HK$453.91m
- -HK$123.52m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.77 | ||
| Price to Tang. Book | 0.77 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -105.66% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The Company has developed a product pipeline of multiple product candidates in-house, covering many indications in metabolic and digestive diseases among which, some are at clinical-stage. The Company’s core product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases. The Company conducts operations in the United States, Mainland China, Hong Kong and Australia.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- February 28th, 2018
- Public Since
- December 22nd, 2023
- No. of Employees
- 68
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 472,821,374
- Address
- South Church Street 103,, SHENZHEN, 518112
- Web
- https://www.hightidetx.com/
- Phone
- Auditors
- Ernst & Young
Upcoming Events for 2511
Similar to 2511
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
What is the HighTide Therapeutics share price?
As of Today at 20:06 UTC, shares in HighTide Therapeutics are trading at HK$0.96. This share price information is delayed by 15 minutes.
How has the HighTide Therapeutics share price performed this year?
Shares in HighTide Therapeutics last closed at HK$0.96 and the price had moved by over the past 365 days. In terms of relative price strength the HighTide Therapeutics share price has matched the FTSE Developed Asia Pacific Index by over the past year.
What are the analyst and broker recommendations for HighTide Therapeutics?
There is no consensus recommendation for this security.
Find out moreWhat is the HighTide Therapeutics dividend yield?
HighTide Therapeutics does not currently pay a dividend.
Does HighTide Therapeutics pay a dividend?
HighTide Therapeutics does not currently pay a dividend.
When does HighTide Therapeutics next pay dividends?
HighTide Therapeutics does not currently pay a dividend.
How do I buy HighTide Therapeutics shares?
To buy shares in HighTide Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of HighTide Therapeutics?
As of the previous close price of HK$0.96, shares in HighTide Therapeutics had a market capitalisation of HK$453.91m.
Where are HighTide Therapeutics shares listed?
Here are the trading details for HighTide Therapeutics:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2511
What kind of share is HighTide Therapeutics?
Based on an overall assessment of its quality, value and momentum HighTide Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a HighTide Therapeutics share price forecast for 2024?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the HighTide Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like HighTide Therapeutics. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -74.61%.
As of the last closing price of HK$0.96, shares in HighTide Therapeutics were trading -68.98% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the HighTide Therapeutics PE Ratio?
The HighTide Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$0.96.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of HighTide Therapeutics?
We do not have data on HighTide Therapeutics' directors